IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and https://t.co/7awBk16ZrQ

Stopping therapy in GCA At #ACR25 we saw the SELECT-GCA extension data presented in the first plenary session, looking at the second year after the 52 week original study, comparing upadacitinib versus placebo in GCA. In this second year, patients in remission on upadacitinib https://t.co/GaYNWr3Sjq

Weight Loss as a Therapeutic Goal in PsA PsA is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At #ACR25, 3 compelling studies spanning pharmacologic, lifestyle, and longitudinal https://t.co/Q6IFGn5zCI

IgG4: Rare, but new treatments on the horizon IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis. https://t.co/v07Kp5tQXg https://t.co/rIvOF0mrM1

Do Patients with Rheumatic Diseases 'Weather' the Storm? Dr. Janet Pope reports on abstract 0164 (Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases) presented at #acr25. https://t.co/rY3T6tWsgu https://t.co/vdgT2DB5lH

Upadacitinib: revisiting safety data in RA and GCA For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive. Yet in practice, https://t.co/6Wes2npkFd

#ACR25 Best Abstracts - Day 3 Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at #ACR25, Here are several of the best abstracts from Day 3, as chosen https://t.co/fOgXSiIWzC

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention At #ACR25, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological https://t.co/OIgh8JQsFa

A Halloween ACR Guidance (10.31.25) Dr. Jack Cush recaps #ACR25 with suggestions on how to best learn ACR25 content from RheumNow and our Videos and podcasts. https://t.co/ik5n4jA3LK https://t.co/lr65m8kRxx

The Great Debate – Who Really Won? #ACR25 https://t.co/bh0wxXpVXa https://t.co/Wr8eeW1KsQ

The Decade Ahead: Predicting Long-Term Proteinuria Risk in SLE Lupus nephritis affects almost half of patients with SLE and conveys a mortality rate of up to 30% at 10 years, with at least 10-22% of patients developing end-stage kidney disease. Early detection and diagnosis are https://t.co/ggoA2KsqXg